Clinical Trials · NCT05161195
Roll-over Study to Allow Continued Access to Ribociclib
- Phase
- Phase 4
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 134
- Start date
- Jul 2022
- Locations
- 73 sites, 22 countries
- Primary endpoint
- Percentage of participants with treatment-emergent adverse events (AES)